CGEM Stock Overview
A biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
My Notes
Capture your thoughts, links and company narrative
Cullinan Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.02 |
| 52 Week High | US$30.19 |
| 52 Week Low | US$10.00 |
| Beta | -0.17 |
| 1 Month Change | -8.17% |
| 3 Month Change | -30.08% |
| 1 Year Change | 17.96% |
| 3 Year Change | -22.10% |
| 5 Year Change | n/a |
| Change since IPO | -59.81% |
Recent News & Updates
Recent updates
Cullinan Therapeutics (NASDAQ:CGEM) Is In A Good Position To Deliver On Growth Plans
Nov 20
Cullinan Therapeutics: Fundraising Capability, Emergence In Autoimmune Disease
Aug 30Checking Into Cullinan Therapeutics
Jun 09Companies Like Cullinan Therapeutics (NASDAQ:CGEM) Are In A Position To Invest In Growth
Apr 23Cullinan Oncology: Modality-Agnostic Approach To Yield Fruit In Coming Years
Sep 22Cullinan Oncology: One Of The Leaders In Cancer Treatment Development
Sep 14Cullinan Oncology grants stock options for 125.7K shares
Sep 02Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth
Jun 24Here's Why We're Not Too Worried About Cullinan Oncology's (NASDAQ:CGEM) Cash Burn Situation
Mar 05Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth
Oct 08Cullinan Oncology: Hub-And-Spoke Business Model For Drug Development
Jun 30Cullinan Oncology (CGEM) Presents At 2021 ASCO Annual Virtual Meeting - Slideshow
Jun 05Cullinan initiated Buy at H.C. Wainwright on pipeline strength
Feb 02Shareholder Returns
| CGEM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.6% | 2.6% | 2.8% |
| 1Y | 18.0% | -3.3% | 24.6% |
Return vs Industry: CGEM exceeded the US Biotechs industry which returned -3.3% over the past year.
Return vs Market: CGEM underperformed the US Market which returned 24.6% over the past year.
Price Volatility
| CGEM volatility | |
|---|---|
| CGEM Average Weekly Movement | 7.8% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CGEM has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CGEM's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 85 | Nadim Ahmed | cullinantherapeutics.com |
Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company’s lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.
Cullinan Therapeutics, Inc. Fundamentals Summary
| CGEM fundamental statistics | |
|---|---|
| Market cap | US$751.14m |
| Earnings (TTM) | -US$143.54m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.9x
P/E RatioIs CGEM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CGEM income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$143.54m |
| Earnings | -US$143.54m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.47 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CGEM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 23:08 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Cullinan Therapeutics, Inc. is covered by 12 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Julian Harrison | BTIG |
| Kaveri Pohlman | BTIG |
| Thomas Shrader | BTIG |